Citation Impact
Citing Papers
Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
2009 StandoutNobel
Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival
2014 StandoutNobel
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
2019 StandoutNobel
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials
2020
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
2017 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Regulation of Type II Transmembrane Serine Proteinase TMPRSS6 by Hypoxia-inducible Factors
2010 StandoutNobel
HIF Hydroxylase Pathways in Cardiovascular Physiology and Medicine
2015 StandoutNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
2011
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
2009 Standout
HIF-1: upstream and downstream of cancer metabolism
2009 StandoutNobel
Regulation of cancer cell metabolism by hypoxia-inducible factor 1
2008 StandoutNobel
Cancer to bone: a fatal attraction
2011 Standout
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
2008 Standout
AP-1: a double-edged sword in tumorigenesis
2003 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Hypoxia and Inflammation
2011 Standout
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines
2006
GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
2010
Suppression of Ras-stimulated transformation by the JNK signal transduction pathway
2003
MAP kinase signalling pathways in cancer
2007 Standout
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI
2019 StandoutNobel
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer
2013 StandoutNobel
Four-and-a-Half LIM Domain Proteins Inhibit Transactivation by Hypoxia-inducible Factor 1
2012 StandoutNobel
Regulation of cancer cell metabolism
2011 Standout
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney Cancer
2015 StandoutNobel
Oncofetal reprogramming in tumour development and progression
2022
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Hepatocellular carcinoma
2022 Standout
The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases
2011 StandoutNobel
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
RNA Pseudouridylation in Physiology and Medicine: For Better and for Worse
2017
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
Adipocyte Pseudohypoxia Suppresses Lipolysis and Facilitates Benign Adipose Tissue Expansion
2014 StandoutNobel
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
2013 StandoutNobel
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Thyroid Hormone Regulation of Metabolism
2014 Standout
Obesity and chronic kidney disease
2022
A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA
2022 StandoutNobel
Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2/HIF‐2 pathway
2015 StandoutNobel
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation
2006
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
2001
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
2020
Works of Chen Huang being referenced
Human Gastric Cancer Kinase Profile and Prognostic Significance of MKK4 Kinase
2000
Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis
2012
Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial
2021
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
2020
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
2019
Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis
2007
Clinical significance of AXL kinase family in gastric cancer.
2002